Prospects for pharmacological targeting of pseudokinases

被引:0
作者
Jennifer E. Kung
Natalia Jura
机构
[1] University of California,Cardiovascular Research Institute
[2] San Francisco,Department of Cellular and Molecular Pharmacology
[3] University of California,undefined
[4] San Francisco,undefined
来源
Nature Reviews Drug Discovery | 2019年 / 18卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Pseudokinases are members of the protein kinase superfamily but signal primarily through noncatalytic mechanisms. Many pseudokinases contribute to the pathologies of human diseases, yet they remain largely unexplored as drug targets owing to challenges associated with modulation of their biological functions. Our understanding of the structure and physiological roles of pseudokinases has improved substantially over the past decade, revealing intriguing similarities between pseudokinases and their catalytically active counterparts. Pseudokinases often adopt conformations that are analogous to those seen in catalytically active kinases and, in some cases, can also bind metal cations and/or nucleotides. Several clinically approved kinase inhibitors have been shown to influence the noncatalytic functions of active kinases, providing hope that similar properties in pseudokinases could be pharmacologically regulated. In this Review, we discuss known roles of pseudokinases in disease, their unique structural features and the progress that has been made towards developing pseudokinase-directed therapeutics.
引用
收藏
页码:501 / 526
页数:25
相关论文
共 50 条
[21]   Pharmacological Targeting of Biological Barriers [J].
Wilhelm, Imola .
CURRENT PHARMACEUTICAL DESIGN, 2016, 22 (35) :5311-5312
[22]   Pharmacological targeting of the cancer epigenome [J].
Mabe, Nathaniel W. ;
Perry, Jennifer A. ;
Malone, Clare F. ;
Stegmaier, Kimberly .
NATURE CANCER, 2024, 5 (06) :844-865
[23]   Pharmacological Targeting of the Epidermal Barrier [J].
Kemeny, Lajos ;
Nagy, Nikoletta ;
Csoma, Zsanett ;
Szabo, Kornelia ;
Eros, Gabor .
CURRENT PHARMACEUTICAL DESIGN, 2016, 22 (35) :5373-5381
[24]   Pharmacological targeting of phosphoglycolate phosphatase [J].
Gohla, A. ;
Jeanclos, E. ;
Schloetzer, J. ;
von Kries, J. P. ;
Schindelin, H. .
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2020, 393 (SUPPL 1) :23-24
[25]   Pharmacological background of EGFR targeting [J].
Castillo, L ;
Etienne-Grimaldi, MC ;
Fischel, JL ;
Formento, P ;
Magné, N ;
Milano, G .
ANNALS OF ONCOLOGY, 2004, 15 (07) :1007-1012
[26]   Pharmacological consequences of EGFR targeting [J].
Milano, G ;
Magné, N .
BULLETIN DU CANCER, 2003, 90 :S197-S201
[27]   TARGETING PROSPECTS FOR A NEW PRODUCT [J].
KOTLER, P ;
ZALTMAN, G .
JOURNAL OF ADVERTISING RESEARCH, 1976, 16 (01) :7-18
[28]   Pseudokinases, Tribbles Proteins and Cancer [J].
Velasco, Guillermo ;
Link, Wolfgang .
CANCERS, 2023, 15 (14)
[29]   Improving Prospects for Targeting RAS [J].
Singh, Harshabad ;
Longo, Dan L. ;
Chabner, Bruce A. .
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (31) :3650-+
[30]   Nucleotide-binding mechanisms in pseudokinases [J].
Hammaren, Henrik M. ;
Virtanen, Anniina T. ;
Silvennoinen, Olli .
BIOSCIENCE REPORTS, 2016, 36